Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $15.43 in the last session, up 1.85% from day before closing price of $15.15. In other words, the price has increased by $1.85 from its previous closing price. On the day, 1.76 million shares were traded. DAWN stock price reached its highest trading level at $15.63 during the session, while it also had its lowest trading level at $14.83.
Ratios:
We take a closer look at DAWN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 14.55 and its Current Ratio is at 14.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 31 ’24 when Blackman Samuel C. sold 500 shares for $16.02 per share. The transaction valued at 8,010 led to the insider holds 1,097,035 shares of the business.
SAMUEL BLACKMAN bought 30,000 shares of DAWN for $434,100 on Oct 31 ’24. On Sep 10 ’24, another insider, Blackman Samuel C., who serves as the HEAD OF R&D of the company, sold 30,000 shares for $14.22 each. As a result, the insider received 426,675 and left with 1,097,535 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1556053760 and an Enterprise Value of 1000290304. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.26 while its Price-to-Book (P/B) ratio in mrq is 2.80. Its current Enterprise Value per Revenue stands at 9.811 whereas that against EBITDA is -4.867.
Stock Price History:
Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $10.90. The 50-Day Moving Average of the stock is 8.25%, while the 200-Day Moving Average is calculated to be 5.49%.
Shares Statistics:
According to the various share statistics, DAWN traded on average about 975.32K shares per day over the past 3-months and 1341490 shares per day over the past 10 days. A total of 87.23M shares are outstanding, with a floating share count of 68.16M. Insiders hold about 32.41% of the company’s shares, while institutions hold 64.38% stake in the company. Shares short for DAWN as of 1728950400 were 15976358 with a Short Ratio of 16.38, compared to 1726185600 on 15104667. Therefore, it implies a Short% of Shares Outstanding of 15976358 and a Short% of Float of 19.15.
